Detalhe da pesquisa
1.
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
Ann Oncol
; 33(11): 1168-1178, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35973665
2.
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).
Ann Oncol
; 31(1): 79-87, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31912800
3.
Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87.
Ann Oncol
; 31(8): 1094, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32507672
4.
Did the Chernobyl incident cause an increase in Type 1 diabetes mellitus incidence in children and adolescents?
Diabetologia
; 47(1): 147-8, 2004 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-14658035